Sugi Predict

Sugi Predict / Compounds / SCHEMBL1008255

SCHEMBL1008255

SCHEMBL1008255

COc1cccc(Oc2cnn(C(CC3CCCC3)C(=O)O)c(=O)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 2/20 0.39
▸ CTSL P07711 1/20 0.39
▸ MTNR1B P49286 4/20 0.38
▸ MTNR1A P48039 3/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ NPY5R Q15761 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ PDE4A P27815 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ PDE4C Q08493 1/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ PDE1C Q14123 1/20 0.36
▸ HRH3 Q9Y5N1 2/20 0.36
▸ NPBWR1 P48145 1/20 0.36
▸ GCK P35557 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.35
▸ ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008862 0.93 NPY5R (0.41) CTSSCTSLNPY5RPDE1C
SCHEMBL1007921 0.91 NPBWR1 (0.44) CTSSCTSLNPY5RRAB9ANPBWR1
SCHEMBL1009307 0.90 NPY5R (0.43) CTSSCTSLNPY5RPDE1CHRH3
SCHEMBL1009446 0.88 NPBWR1 (0.37) CTSSCTSLRAB9ANPBWR1GCK
SCHEMBL1008428 0.88 ABL1 (0.38) HRH3
SCHEMBL1008741 0.86 LPAR1 (0.39) PDE4APDE4BPDE4CPDE4D
SCHEMBL1008797 0.85 PPARG (0.39) GCKADORA1
SCHEMBL1007742 0.85 GPR132 (0.42) NPY5RRAB9AHRH3GCK
SCHEMBL1009289 0.85 NPY5R (0.44) CTSSCTSLCYP1A2CYP2C19SMN1; SMN2
SCHEMBL1008946 0.84 PTGDR2 (0.37) CTSSCTSLRAB9ANPBWR1GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK CTSS 1530/4885CTSL 1894/4885MTNR1B 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.